The Na/K-ATPase 1 and c-Src form signaling complex under native condition: a crosslinking approach
In 2021, Wegovy, which is another brand name for Semaglutide, was FDA approved for weight loss
Inhibition of nonalcoholic fatty liver disease in mice by selective inhibition of mTORC1
*Correspondence: Hitoshi Ando, [email protected] This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Aoki K, Kamiyama H, Takihata M, Taguri M, Shibata E, Shinoda K, et al
Using Abilify in cases can pose potential risks, including severe allergic reactions, worsening of pre-existing conditions, or unexpected side effects